

GOVERNMENT OF ANDHRA PRADESH
HEALTH, MEDICAL & FAMILY WELFARE DEPARTMENT

Order No. 107/COVID-19/2021

Dated: 25/04/2021

COVID Instant Order – 107

Sub: Guidelines for usage of Remdesivir in COVID-19

Ref: 1. Video Conference with Districts by Hon'ble Minister of Urban Development, GoAP on COVID-19, dt: 24.04.2021.
2. Meeting of the AP State Expert Committee on Clinical Management of COVID-19, Dt 24.04.2021 & 25.04.2021.



In view of current COVID-19 situation, Guidelines for usage of Remdesivir in COVID-19 is hereby attached.

All Collectors & Special Officers are requested to take immediate necessary action.

Encl: Guidelines for usage of Remdesivir in COVID-19



Principal Secretary To Government

To

The All Collectors and District Magistrates in the State for immediate action

The All Joint Collectors and Addl. District Magistrates (Development) for necessary action

All the DM&HO's in the State for necessary action and implementation

Guidelines for usage of Remdesivir in COVID-19

Introduction

Remdesivir is an intravenous nucleotide prodrug of adenosine analogue. It binds to the viral RNA-dependent RNA polymerase and inhibits viral replication through premature termination of RNA transcription. This drug has been approved as Emergency Use Authorization/off label use in COVID-19 with specific indications.

The evidence at hand (ACTT1 trial, Solidarity trial) as on date points that Remdesivir doesn't prevent oxygen requirement, doesn't prevent progression to mechanical ventilation, doesn't reduce mortality; only it hastens the recovery period from 15 days to 10 days. Based on the evidence available as on date, the following recommendation is made.

Prerequisite

1. To be used only on Hospitalized patients who are admitted as per Admission Guidelines for COVID-19 Hospitals as on date.

Indications

1. For Moderate to Severe disease patients those who require supplemental oxygen.

AND

2. Who are within 10 days of onset of symptom/s only.

Course

The recommended treatment course is 5 days in patients on oxygen. 200mg Intra-Venous, loading dose on day 1, followed by 100mg OD, Intra-Venous, for next 4 days.


Contraindications

1. Hepatic dysfunction: AST/ALT > 5 times upper limit of normal (ULN).
2. Renal dysfunction: eGFR < 30ml/min/m² or need for haemodialysis.
3. Pregnancy and lactating mother (but consider when benefit outweighs the risk on case to case basis).
4. Children <12 years of age.

Caution

1. Not to use in home settings.
2. If Heart Rate is below 45 beats per minute persistently, Remdesivir IV drip should be stopped, ECG to be taken & Cardiac evaluation should be done. Take further Clinical action accordingly.

End of content



K. Anandil

~~200000~~

Carb.

BV. Anil ~~1/2~~

Ram

S. Nalin

1/2

End of the document